Forum Topic News
  • Conversation: GSK’s RSV vaccine granted FDA priority review for use in adults aged 50 to 59 years

    • February 8, 2024 4:29 PM GMT
      • Post(s)
        697

      GSK’s RSV vaccine granted FDA priority review for use in adults aged 50 to 59 years

      RSV is a common contagious virus characterised by several mild, cold-like symptoms. Although most people can recover within a week or two, certain populations are at a higher risk for severe disease, such as older adults, the immunocompromised and those with underlying medical conditions.
      Arexvy has already been approved in the US, Europe and several other countries to protect adults aged 60 years and older against RSV-caused lower respiratory tract disease (LRTD).
      GSK’s application to extend the indication is supported by results from a late-stage trial evaluating the immune response and safety of Arexvy in adults aged 50 to 59 years, including those at increased risk for RSV-LRTD due to underlying medical conditions.
      The company recently shared positive results from the trial, which showed that Arexvy elicited an immune response in this population, including those with chronic pulmonary disease, cardiovascular disease, kidney disease, liver disease or diabetes, that was non-inferior to that observed in adults aged 60 and above.
      The co-primary endpoint was also met for the broader group of adults in this age group, GSK said in the October readout, adding that safety and reactogenicity data was consistent with results from the initial phase 3 programme of Arexvy.
      Read more: https://www.pmlive.com/pharma_news/gsks_rsv_vaccine_granted_fda_priority_review_for_use_in_adults_aged_50_to_59_years_1507886

Add Reputation

Do you want to add reputation for this member by this post?

or cancel